Analysis of the effects of dapagliflozin on cardiac myocyte injury markers and left ventricular diastolic function in heart failure patients with preserved ejection fraction after percutaneous coronary intervention

The objective of this study was to analyze the effects of Dapagliflozin on cardiac myocyte injury markers and left ventricular diastolic function in patients with Heart Failure with Preserved Ejection Fraction (HF-PEF) after Percutaneous Coronary Intervention (PCI). The study included 120 HF-PEF patients post-PCI treated at our hospital between May 2021 and May 2024. Patients were divided into two groups: conventional therapy (n=49) and Dapagliflozin plus conventional therapy (n=71). Serum Cardiac Troponin I (cTnI) and Serum Amyloid A (SAA) were measured. Left ventricular function was assessed by Ejection Fraction (EF) and the E/e' ratio. The incidence of Major Adverse Cardiovascular Events (MACE) was also recorded. After treatment, the Dapagliflozin group showed significantly lower cTnI and SAA levels compared to the conventional group (p<0.05). EF was higher and E/e' ratio was lower in the Dapagliflozin group (p<0.05). The incidence of MACE was reduced to 1.41% versus 12.24% in the conventional group (p<0.05). In conclusion, Dapagliflozin effectively reduces cardiac myocyte injury markers, improves left ventricular diastolic function, and lowers the incidence of MACE in HF-PEF patients after PCI, demonstrating significant translational benefits for cardiac muscle function.